{"id":"triamcinolone","rwe":[],"_fda":{"id":"16bdbe70-e1b5-4134-9f18-0aac91706f2d","set_id":"00cb6cd0-da04-4c87-a60c-c891666a6574","openfda":{"spl_id":["16bdbe70-e1b5-4134-9f18-0aac91706f2d"],"brand_name":["Trilona"],"spl_set_id":["00cb6cd0-da04-4c87-a60c-c891666a6574"],"package_ndc":["73086-104-60","67877-251-30"],"product_ndc":["73086-104"],"generic_name":["TRIAMCINOLONE ACETONIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Skya Health, LLC"],"is_original_packager":[true]},"version":"1","pregnancy":["PREGNANCY CATEGORY C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time."],"overdosage":["OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS )."],"description":["DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Chemically triamcinolone acetonide is pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16, 17-[(1-methylethylidene) bis(oxy)]-(11β16α) Its structural formula is: Each gram of Triamcinolone Acetonide Cream USP, 0.1% contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Structure"],"precautions":["PRECAUTIONS GENERAL Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. INFORMATION FOR PATIENTS Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician 4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. LABORATORY TESTS The following tests may be helpful in evaluating the HPA axis suppression: Urinary free cortisol test ACTH stimulation test CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. PREGNANCY CATEGORY C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. NURSING MOTHERS It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. PEDIATRIC USE Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children."],"how_supplied":["HOW SUPPLIED Triamcinolone Acetonide Cream USP, 0.1%, 30 g - (2 Tubes) 30 grams 2 tubes NDC 73086-104-60 Store at 20°–25°C (68°–77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing. PRINTED IN USA Packaged by: Skya Health, LLC. Corona, CA 92882 Questions or Comments Call: 866-759-2669"],"pediatric_use":["PEDIATRIC USE Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children."],"effective_time":"20260414","nursing_mothers":["NURSING MOTHERS It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman."],"laboratory_tests":["LABORATORY TESTS The following tests may be helpful in evaluating the HPA axis suppression: Urinary free cortisol test ACTH stimulation test"],"adverse_reactions":["ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria."],"contraindications":["CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation."],"general_precautions":["GENERAL Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses . ( See DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile."],"indications_and_usage":["INDICATIONS & USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."],"information_for_patients":["INFORMATION FOR PATIENTS Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician 4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings."],"dosage_and_administration":["DOSAGE & ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted."],"spl_product_data_elements":["Trilona Triamcinolone Acetonide Triamcinolone Acetonide Triamcinolone Acetonide TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE WATER MINERAL OIL PROPYLENE GLYCOL SORBITOL SOLUTION CETYL PALMITATE SORBIC ACID POTASSIUM SORBATE"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - Label NDC: 73086-104-60 Trilona TM Rx Only Kit Includes: Triamcinolone Acetonide Cream USP, 0.1%, 30 g - (2 Tubes) Silicone Tape Roll - (1 Roll) Sterile Gauze Pads - (20 count) Triamcinolone Acetonide Cream USP Each gram contains 1 mg Triamcinolone Acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid and potassium sorbate. Usual Dosage: 2 to 3 applications daily. See package insert for full prescribing information. TO OPEN: Use cap to puncture seal. IMPORTANT: Do not use if seal has been punctured or is not visible. See enclosed insert for full prescribing information. Store at 20 o to 25 o C (68 o to 77 o F) [see USP Controlled Room Temperature]. Keep this and all medication out of reach of children. For external use only. Not for ophthalmic use. Packaged by: Skya Health, LLC. Corona, CA 92882 Questions or Comments Call: 866-759-2669 Skya Health PRINCIPAL DISPLAY PANEL - Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results."]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"ANXA1","category":"gene"},{"label":"PGR","category":"gene"},{"label":"A01AC01","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Implant","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acquired thrombocytopenia","category":"indication"},{"label":"Acute lymphoid leukemia","category":"indication"},{"label":"Adrenal cortical hypofunction","category":"indication"},{"label":"Adrenogenital disorder","category":"indication"},{"label":"Allergic Rhinitis Prevention","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Approved 1950s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"5137 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"2700 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"2254 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"2222 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"2062 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1976 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1965 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"1757 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"1686 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1644 reports"}],"drugInteractions":[{"url":"/drug/aripiprazole","drug":"aripiprazole","action":"Monitor closely","effect":"May interact with Aripiprazole","source":"DrugCentral","drugSlug":"aripiprazole"},{"url":"/drug/quetiapine","drug":"quetiapine","action":"Monitor closely","effect":"May interact with Quetiapine Fumarate","source":"DrugCentral","drugSlug":"quetiapine"},{"url":"/drug/risperidone","drug":"risperidone","action":"Monitor closely","effect":"May interact with Risperidone","source":"DrugCentral","drugSlug":"risperidone"},{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"skin atrophy","drugRate":"reported","severity":"unknown"},{"effect":"miliaria","drugRate":"reported","severity":"unknown"},{"effect":"striae","drugRate":"reported","severity":"unknown"},{"effect":"maceration of the skin","drugRate":"reported","severity":"unknown"},{"effect":"allergic contact dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"perioral dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"hypopigmentation","drugRate":"reported","severity":"unknown"},{"effect":"acneiform eruptions","drugRate":"reported","severity":"unknown"},{"effect":"hypertrichosis","drugRate":"reported","severity":"unknown"},{"effect":"folliculitis","drugRate":"reported","severity":"unknown"},{"effect":"dryness","drugRate":"reported","severity":"unknown"},{"effect":"irritation","drugRate":"reported","severity":"unknown"},{"effect":"itching","drugRate":"reported","severity":"unknown"},{"effect":"burning","drugRate":"reported","severity":"unknown"},{"effect":"secondary infection","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute tuberculosis","Anastomosis of intestine","Arginase deficiency","Arginosuccinate Lyase Deficiency","Atrophoderma","Avascular necrosis of bone","Bacterial infectious disease","Bilateral cataracts","Candidiasis of mouth","Cerebral malaria","Cerebral trauma","Chronic heart failure","Cirrhosis of liver","Citrullinemia","Congenital hyperammonemia, type I","Diabetes mellitus","Disease caused by parasite","Disease of liver","Disorder of muscle","Diverticulitis of gastrointestinal tract","Edema","Epistaxis","Exposure to varicella","Fungal infection of eye","Gastritis"],"specialPopulations":{"Pregnancy":"Topical corticosteroids should be used during pregnancy only after careful consideration of the potential benefits and risks. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.","Paediatric use":"Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushings syndrome than mature patients because of larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushings syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain."}},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0338/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$12","description":"TRIAMCINOLONE 0.025% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TRIAMCINOLONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:14:34.637111+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Triamcinolone","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:14:43.328974+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:14:41.837296+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T02:14:33.249072+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRIAMCINOLONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:14:42.755647+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:14:31.638083+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T02:14:44.288549+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:14:43.327902+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200449/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:14:43.226263+00:00"}},"allNames":"rodinolone","offLabel":[],"synonyms":["triamcinolone","triamcinlon","triamcinolon","rodinolone"],"timeline":[{"date":"1957-12-03","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Rodinolone, also known as Triamcinolone, is a corticosteroid medication that targets the glucocorticoid receptor. Originally developed in the 1950s, it is now off-patent and available from multiple generic manufacturers. Triamcinolone is used to treat a range of conditions, including allergic reactions, skin conditions, and adrenal insufficiency. It is a small molecule that works by binding to the glucocorticoid receptor, which helps to reduce inflammation and suppress the immune system. As a result, it is used to prevent and treat various inflammatory and autoimmune disorders.","approvals":[{"date":"1957-12-03","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Rodinolone","ecosystem":[{"indication":"Acquired thrombocytopenia","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null},{"indication":"Acute lymphoid leukemia","otherDrugs":[{"name":"asparaginase","slug":"asparaginase","company":"Merck"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"clofarabine","slug":"clofarabine","company":"Genzyme"}],"globalPrevalence":null},{"indication":"Adrenal cortical hypofunction","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null},{"indication":"Adrenogenital disorder","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null},{"indication":"Allergic Rhinitis Prevention","otherDrugs":[{"name":"budesonide","slug":"budesonide","company":""},{"name":"desonide","slug":"desonide","company":"Perrigo New York"},{"name":"flunisolide","slug":"flunisolide","company":""},{"name":"mometasone furoate","slug":"mometasone-furoate","company":"Merck Sharp Dohme"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Alopecia areata","otherDrugs":[{"name":"baricitinib","slug":"baricitinib","company":"Eli Lilly And Co"},{"name":"ritlecitinib","slug":"ritlecitinib","company":"Pfizer Inc"},{"name":"triamcinolone acetonide","slug":"triamcinolone-acetonide","company":"Apothecon"},{"name":"triamcinolone diacetate","slug":"triamcinolone-diacetate","company":"Sandoz"}],"globalPrevalence":null},{"indication":"Angioedema","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""}],"globalPrevalence":200000}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"ANXA1","source":"DrugCentral","target":"Annexin A1","protein":"Annexin A1"},{"gene":"PGR","source":"DrugCentral","target":"Progesterone receptor","protein":"Progesterone receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"","oneSentence":"","technicalDetail":"Triamcinolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor (GR), which is a transcription factor that regulates the expression of genes involved in inflammation and immune response. By binding to GR, triamcinolone activates or represses the transcription of target genes, leading to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Triamcinolone","title":"Triamcinolone","extract":"Triamcinolone is a glucocorticoid used to treat certain skin diseases, allergies, and rheumatic disorders among others. It is also used to prevent worsening of asthma and chronic obstructive pulmonary disease (COPD). It can be taken in various ways including by mouth, injection into a muscle, and inhalation.","wiki_society_and_culture":"== Society and culture ==\nIn 2010, Teva and Perrigo launched the first generic inhalable triamcinolone.\n\nAccording to Chang et al. (2014), \"Triamcinolone acetonide (TA) is classified as an S9 glucocorticoid in the 2014 Prohibited List published by the World Anti-Doping Agency, which caused it to be prohibited in international athletic competition when administered orally, intravenously, intramuscularly or rectally\"."},"commercial":{"launchDate":"1957","_launchSource":"DrugCentral (FDA 1957-12-03, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2725","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TRIAMCINOLONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRIAMCINOLONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Triamcinolone","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:07:28.379936","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:14:47.753413+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dexamethasone","drugSlug":"dexamethasone","fdaApproval":"1958-10-30","patentExpiry":"Oct 7, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"hydrocortisone","drugSlug":"hydrocortisone","fdaApproval":"1952-08-05","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prednisolone","drugSlug":"prednisolone","fdaApproval":"1955-06-21","genericCount":42,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"triamcinolone","indications":{"approved":[{"name":"Acquired thrombocytopenia","source":"DrugCentral","snomedId":74576004,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Acute lymphoid leukemia","source":"DrugCentral","snomedId":91857003,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Adrenal cortical hypofunction","source":"DrugCentral","snomedId":386584007,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Adrenogenital disorder","source":"DrugCentral","snomedId":267395000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Allergic Rhinitis Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Alopecia areata","source":"DrugCentral","snomedId":68225006,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Angioedema","source":"DrugCentral","snomedId":41291007,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":null,"globalPrevalence":200000,"prevalenceMethod":"curated","prevalenceSource":"Int Arch Allergy Immunol, 2025 (PMID:39827848)"},{"name":"Ankylosing spondylitis","source":"DrugCentral","snomedId":9631008,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":null,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Care Res (Hoboken), 2016 (PMID:26713432)"},{"name":"Aphthous ulcer of mouth","source":"DrugCentral","snomedId":426965005,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Articular gout","source":"DrugCentral","snomedId":48440001,"regulator":"FDA","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Aspiration pneumonitis","source":"DrugCentral","snomedId":155597006,"regulator":"FDA"},{"name":"Asthma","source":"DrugCentral","snomedId":195967001,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Asthma management","source":"DrugCentral","snomedId":406162001,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Autoimmune disease","source":"DrugCentral","snomedId":85828009,"regulator":"FDA"},{"name":"Autoimmune hemolytic anemia","source":"DrugCentral","snomedId":413603009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":880000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (20066507[PMID])"},{"name":"Berylliosis","source":"DrugCentral","snomedId":8247009,"regulator":"FDA"},{"name":"Bursitis","source":"DrugCentral","snomedId":84017003,"regulator":"FDA"},{"name":"Candidiasis of skin","source":"DrugCentral","snomedId":49883006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":138000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Infect Dis, 2018 (PMID:30078662)"},{"name":"Cerebral edema","source":"DrugCentral","snomedId":2032001,"regulator":"FDA"},{"name":"Chronic Non-Allergic Rhinitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Congenital adrenal hyperplasia","source":"DrugCentral","snomedId":237751000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":800000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Congenital hypoplastic anemia","source":"DrugCentral","snomedId":88854002,"regulator":"FDA"},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Crohn's disease","source":"DrugCentral","snomedId":34000006,"regulator":"FDA","usPrevalence":780000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"},{"name":"Cystic Aponeurosis Tumor","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Dermatitis herpetiformis","source":"DrugCentral","snomedId":111196000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2160000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet ([EXPERT])"},{"name":"Diagnostic Test for Cushing's Syndrome","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Disorder of eye","source":"DrugCentral","snomedId":371405004,"regulator":"FDA"},{"name":"Disorder of musculoskeletal system","source":"DrugCentral","snomedId":928000,"regulator":"FDA"},{"name":"Disorder of skin","source":"DrugCentral","snomedId":95320005,"regulator":"FDA"},{"name":"Edema of larynx","source":"DrugCentral","snomedId":51599000,"regulator":"FDA"},{"name":"Epicondylitis","source":"DrugCentral","snomedId":73583000,"regulator":"FDA"},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA"},{"name":"Erythema multiforme","source":"DrugCentral","snomedId":36715001,"regulator":"FDA"},{"name":"Erythroblastic Anemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Erythroderma","source":"DrugCentral","snomedId":399992009,"regulator":"FDA"},{"name":"Follicular non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":308121000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":123507000,"prevalenceMethod":"curated","prevalenceSource":"J Insur Med, 2023 (PMID:37725503)"},{"name":"Giant cell arteritis","source":"DrugCentral","snomedId":414341000,"regulator":"FDA","prevalenceClass":"1-9 / 100 000","globalPrevalence":712000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (11136884[PMID])"},{"name":"Gingival Disorders","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA"},{"name":"Hodgkin's disease","source":"DrugCentral","snomedId":118599009,"regulator":"FDA"},{"name":"Humoral hypercalcemia of malignancy","source":"DrugCentral","snomedId":47709007,"regulator":"FDA"},{"name":"Idiopathic thrombocytopenic purpura","source":"DrugCentral","snomedId":32273002,"regulator":"FDA"},{"name":"Inflammatory bowel disease","source":"DrugCentral","snomedId":24526004,"regulator":"FDA"},{"name":"Juvenile rheumatoid arthritis","source":"DrugCentral","snomedId":410795001,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Keloid scar","source":"DrugCentral","snomedId":33659008,"regulator":"FDA"},{"name":"Lichen planus","source":"DrugCentral","snomedId":4776004,"regulator":"FDA"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA"},{"name":"Löffler's syndrome","source":"DrugCentral","snomedId":64936001,"regulator":"FDA"},{"name":"Miliary tuberculosis","source":"DrugCentral","snomedId":47604008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":1280000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Multiple sclerosis","source":"DrugCentral","snomedId":24700007,"regulator":"FDA"},{"name":"Mycosis fungoides","source":"DrugCentral","snomedId":118618005,"regulator":"FDA"},{"name":"Necrobiosis lipoidica diabeticorum","source":"DrugCentral","snomedId":56391002,"regulator":"FDA"},{"name":"Nephrotic syndrome","source":"DrugCentral","snomedId":52254009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":8800,"prevalenceMethod":"curated","prevalenceSource":"Orphanet ([EXPERT]_17162528[PMID])"},{"name":"Non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":118601006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":123507000,"prevalenceMethod":"curated","prevalenceSource":"J Insur Med, 2023 (PMID:37725503)"},{"name":"Pemphigus","source":"DrugCentral","snomedId":65172003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":1440000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency[INST])"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Post traumatic osteoarthritis","source":"DrugCentral","snomedId":699262001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":655000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Res Ther, 2023 (PMID:36991481)"},{"name":"Primary adrenocortical insufficiency","source":"DrugCentral","snomedId":373662000,"regulator":"FDA"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA"},{"name":"Psoriasis","source":"DrugCentral","snomedId":9014002,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Psoriasis with arthropathy","source":"DrugCentral","snomedId":33339001,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Rheumatic heart disease","source":"DrugCentral","snomedId":23685000,"regulator":"FDA"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Sarcoidosis","source":"DrugCentral","snomedId":31541009,"regulator":"FDA"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"},{"name":"Severe Ocular Inflammation","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Severe adrenal insufficiency","source":"DrugCentral","snomedId":24867002,"regulator":"FDA"},{"name":"Subacute bursitis","source":"DrugCentral","snomedId":109298000,"regulator":"FDA"},{"name":"Sympathetic uveitis","source":"DrugCentral","snomedId":75315001,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":3040000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (8407119[PMID])"},{"name":"Synovitis","source":"DrugCentral","snomedId":416209007,"regulator":"FDA"},{"name":"Synovitis due to Osteoarthritis","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":655000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Res Ther, 2023 (PMID:36991481)"},{"name":"Systemic Dermatomyositis","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":602496,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (36581896[PMID]_ORPHANET)"},{"name":"Systemic lupus erythematosus","source":"DrugCentral","snomedId":55464009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":3496000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (36241363[PMID])"},{"name":"Tendinitis","source":"DrugCentral","snomedId":34840004,"regulator":"FDA"},{"name":"Tenosynovitis","source":"DrugCentral","snomedId":67801009,"regulator":"FDA"},{"name":"Thyroiditis","source":"DrugCentral","snomedId":82119001,"regulator":"FDA"},{"name":"Transfusion Reaction Urticaria","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Transfusion reaction due to serum protein reaction","source":"DrugCentral","snomedId":72284000,"regulator":"FDA"},{"name":"Transplanted organ rejection","source":"DrugCentral","snomedId":213148006,"regulator":"FDA"},{"name":"Uveitis","source":"DrugCentral","snomedId":128473001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":3040000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (8407119[PMID])"},{"name":"Vitrectomy Adjunct to Enhance Visualization","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Bronchitis","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":32,"evidenceLevel":"moderate"},{"name":"Carditis","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":11,"evidenceLevel":"moderate"},{"name":"Celiac disease","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":7,"evidenceLevel":"emerging"},{"name":"Chronic hepatitis","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":11,"evidenceLevel":"moderate"},{"name":"Chronic obstructive lung disease","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":48,"evidenceLevel":"moderate"},{"name":"Eczema","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Hepatic necrosis","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Hypercalcemia associated with Sarcoidosis","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Multiple myeloma","source":"DrugCentral","drugName":"TRIAMCINOLONE","evidenceCount":15,"evidenceLevel":"moderate"},{"name":"Nasal polyp","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Neonatal Bronchopulmonary Dysplasia","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Pemphigoid","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Pericarditis","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Polyarteritis nodosa","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Polymyalgia rheumatica","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Pseudogout","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Respiratory distress syndrome in the newborn","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Rheumatic fever","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Severe chronic obstructive pulmonary disease","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"Vasculitis","source":"DrugCentral","drugName":"TRIAMCINOLONE"},{"name":"West syndrome","source":"DrugCentral","drugName":"TRIAMCINOLONE"}],"pipeline":[]},"drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"dexamethasone","brandName":"dexamethasone","genericName":"dexamethasone","approvalYear":"1958","relationship":"same-class"},{"drugId":"hydrocortisone","brandName":"hydrocortisone","genericName":"hydrocortisone","approvalYear":"1952","relationship":"same-class"},{"drugId":"prednisolone","brandName":"prednisolone","genericName":"prednisolone","approvalYear":"1955","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05306548","phase":"PHASE4","title":"A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2022-04-08","conditions":["Carpal Tunnel Syndrome"],"enrollment":258,"completionDate":"2028-03"},{"nctId":"NCT07494136","phase":"PHASE4","title":"Dose Dependent Steroid Injections","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05","conditions":["Lumbar Radiculopathy","Sciatica","Back Pain With Radiation"],"enrollment":150,"completionDate":"2027-05"},{"nctId":"NCT06578728","phase":"PHASE4","title":"Local Methotrexate Injections for the Treatment of Nail Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-09-10","conditions":["Nail Psoriasis"],"enrollment":1,"completionDate":"2026-06"},{"nctId":"NCT05845125","phase":"PHASE4","title":"Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone","status":"TERMINATED","sponsor":"Claire Bourgeois","startDate":"2023-05-21","conditions":["Shoulder Pain"],"enrollment":50,"completionDate":"2024-05-21"},{"nctId":"NCT07476209","phase":"NA","title":"Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2026-04-01","conditions":["Radiation Induced Xerostomia"],"enrollment":42,"completionDate":"2027-03-01"},{"nctId":"NCT07493213","phase":"NA","title":"USG-Guided Shoulder Injections in Frozen Shoulder","status":"RECRUITING","sponsor":"Konya Beyhekim Training and Research Hospital","startDate":"2026-04-01","conditions":["Frozen Shoulder","Adhesive Capsulitis","Shoulder Pain","Nociplastic Pain","Neuropathic Pain"],"enrollment":68,"completionDate":"2027-06-30"},{"nctId":"NCT02870738","phase":"PHASE2","title":"Bladder Directed vs. Pelvic Floor Therapy in IC/BPS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corewell Health East","startDate":"2017-04-21","conditions":["Cystitis, Interstitial","Painful Bladder Syndrome"],"enrollment":128,"completionDate":"2026-08"},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":["Kidney Transplantation"],"enrollment":418,"completionDate":"2021-10-29"},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":["Kidney Transplant"],"enrollment":800,"completionDate":"2029-07"},{"nctId":"NCT07168148","phase":"PHASE2","title":"Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2025-11-10","conditions":["Nasal Obstruction","Chronic Rhinitis"],"enrollment":3,"completionDate":"2026-03-19"},{"nctId":"NCT04641351","phase":"PHASE4","title":"Corticosteroid Meniscectomy Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2021-05-27","conditions":["Osteoarthritis, Knee","Meniscus Tear","Meniscus; Degeneration","Synovitis"],"enrollment":150,"completionDate":"2026-08-01"},{"nctId":"NCT05423613","phase":"NA","title":"Microneedling for Burn Hypertrophic Scars","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-01-22","conditions":["Burn Scar"],"enrollment":36,"completionDate":"2026-07-31"},{"nctId":"NCT07129798","phase":"NA","title":"Efficacy and Safety of Myopic Macular Hole Closure Surgery Without Endotamponade Agent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-01-18","conditions":["Macular Hole","Myopia"],"enrollment":20,"completionDate":"2026-12-26"},{"nctId":"NCT07475689","phase":"NA","title":"Sidekick vs Conventional Cannula in Lumbar Medial Branch Radiofrequency Ablation","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","startDate":"2024-08-01","conditions":["Facet Joint Pain; Low Back Pain"],"enrollment":82,"completionDate":"2025-09-24"},{"nctId":"NCT07228104","phase":"PHASE3","title":"Use of Steroid Injections to Prevent the Recurrence of Tracheal Stenosis in Idiopathic Subglottic Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-05-01","conditions":["Idiopathic Subglottic Stenosis"],"enrollment":226,"completionDate":"2032-01"},{"nctId":"NCT07471997","phase":"NA","title":"Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2024-06-20","conditions":["Thyroid Eye Disease, TED"],"enrollment":15,"completionDate":"2025-02-20"},{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":["Breast Cancer Triple Negative Breast Cancer"],"enrollment":30,"completionDate":"2029-03-31"},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":["Geographic Atrophy"],"enrollment":305,"completionDate":"2026-02-23"},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":["Kidney Transplantation"],"enrollment":33,"completionDate":"2024-12-11"},{"nctId":"NCT06917937","phase":"NA","title":"The Additive Effect of Exercise in Addition to Corticosteroid Injection in Plantar Fasciitis","status":"COMPLETED","sponsor":"Kutahya Health Sciences University","startDate":"2018-09-16","conditions":["Plantar Fascitis"],"enrollment":40,"completionDate":"2019-05-05"},{"nctId":"NCT06782529","phase":"PHASE4","title":"Knee Injections for Obese Patients With Knee Arthritis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-01-24","conditions":["Osteoarthritis of Knee"],"enrollment":40,"completionDate":"2027-01-24"},{"nctId":"NCT05844930","phase":"PHASE4","title":"A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2023-01-03","conditions":["Adhesive Capsulitis"],"enrollment":56,"completionDate":"2025-02-04"},{"nctId":"NCT07453238","phase":"PHASE4","title":"Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-04-01","conditions":["Alopecia Areata"],"enrollment":60,"completionDate":"2026-10-01"},{"nctId":"NCT07336368","phase":"PHASE3","title":"Topical Cryotherapy and Keloid/Hypertrophic Scars","status":"RECRUITING","sponsor":"Sonal Choudhary","startDate":"2026-03","conditions":["Keloid Scars","Hypertrophic Scars"],"enrollment":30,"completionDate":"2026-08"},{"nctId":"NCT06004882","phase":"NA","title":"Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-10","conditions":["Peripheral Nerve Stimulation","Genicular Nerves","Chronic Knee Pain"],"enrollment":45,"completionDate":"2027-01-31"},{"nctId":"NCT07004465","phase":"NA","title":"Effectiveness of Vitamin b12 Versus Kenalog on Traumatic Ulcer Associated With Orthodontic Treatment","status":"COMPLETED","sponsor":"Hawraa Ali Abdullah","startDate":"2025-08-19","conditions":["Mouth Ulcer"],"enrollment":82,"completionDate":"2026-02-28"},{"nctId":"NCT07445191","phase":"PHASE2,PHASE3","title":"Efficacy of Triamcinolone-Lidocaine Mix in Trigger Points Injection of Masseter Muscle: Double-blinded, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-01","conditions":["TMJ Pain"],"enrollment":30,"completionDate":"2026-07-01"},{"nctId":"NCT06981767","phase":"PHASE2","title":"Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-02-18","conditions":["Oral Lichen Planus"],"enrollment":42,"completionDate":"2026-06-15"},{"nctId":"NCT04990128","phase":"PHASE3","title":"Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2026-03-01","conditions":["Hip Osteoarthritis"],"enrollment":100,"completionDate":"2027-11"},{"nctId":"NCT05152810","phase":"NA","title":"Effectiveness of Transcranial Magnetic Stimulation (TMS) in Smoking Cessation, Combining Withdrawal Stimulation Followed by Maintenance Stimulation to Prevent Relapse","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-01-06","conditions":["Smoking Cessation"],"enrollment":88,"completionDate":"2025-11-20"},{"nctId":"NCT07433257","phase":"","title":"The Effect of Local Corticosteroid Injection in Carpal Tunnel Syndrome Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2026-03-01","conditions":["Carpal Tunnel Syndrome (CTS)","Type 2 Diabetes Mellitus (T2DM)"],"enrollment":60,"completionDate":"2026-07-31"},{"nctId":"NCT06748404","phase":"PHASE2","title":"TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-01-31","conditions":["Immunotherapy-related Pruritus"],"enrollment":28,"completionDate":"2028-12"},{"nctId":"NCT05992883","phase":"PHASE3","title":"NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-07-28","conditions":["Thumb Osteoarthritis"],"enrollment":240,"completionDate":"2026-12-31"},{"nctId":"NCT06176248","phase":"NA","title":"Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis","status":"RECRUITING","sponsor":"CHU de Reims","startDate":"2024-10-11","conditions":["Adhesive Capsulitis"],"enrollment":62,"completionDate":"2027-03"},{"nctId":"NCT06903936","phase":"NA","title":"Comparison of the Effect of Genicular Nerve Block and Physical Therapy in Patients With Knee Osteoarthritis","status":"RECRUITING","sponsor":"Ahi Evran University Education and Research Hospital","startDate":"2025-09-01","conditions":["Knee Osteoarthritis"],"enrollment":66,"completionDate":"2026-03-01"},{"nctId":"NCT04036188","phase":"EARLY_PHASE1","title":"Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis","status":"RECRUITING","sponsor":"Wright State University","startDate":"2019-10-16","conditions":["Plaque Psoriasis","Vitamin D3"],"enrollment":24,"completionDate":"2026-12"},{"nctId":"NCT07420166","phase":"NA","title":"Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-01-01","conditions":["Keloid"],"enrollment":60,"completionDate":"2025-06-30"},{"nctId":"NCT05436535","phase":"PHASE4","title":"Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-21","conditions":["Atopic Dermatitis"],"enrollment":433,"completionDate":"2025-10-24"},{"nctId":"NCT06988527","phase":"PHASE2,PHASE3","title":"Treatment Outcomes and Patient Satisfaction of Oral Lichen Planus Treatment","status":"RECRUITING","sponsor":"Dar Al Uloom University","startDate":"2025-05-20","conditions":["Erosive Oral Lichen Planus","Atrophic Lichen Planus"],"enrollment":56,"completionDate":"2026-06-30"},{"nctId":"NCT07409571","phase":"NA","title":"Palatal Wound Healing After Free Gingival Graft Surgery","status":"RECRUITING","sponsor":"Kahramanmaras Sutcu Imam University","startDate":"2026-01-02","conditions":["Gingival Recession, Localized","Postoperative Morbidity","Palatal Donor Site Wound Healing"],"enrollment":34,"completionDate":"2026-03-31"},{"nctId":"NCT04002362","phase":"PHASE2","title":"Symptom Clusters in Children With Exacerbation-prone Asthma","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-13","conditions":["Asthma in Children"],"enrollment":68,"completionDate":"2025-12-24"},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":["Breast Cancer"],"enrollment":110,"completionDate":"2029-02-21"},{"nctId":"NCT07405489","phase":"","title":"Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone for Acute Ocular VKH","status":"COMPLETED","sponsor":"Benha University","startDate":"2021-01-01","conditions":["VKH Syndrome"],"enrollment":30,"completionDate":"2025-12-01"},{"nctId":"NCT07141407","phase":"NA","title":"Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-04-01","conditions":["Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphatic System Neoplasm"],"enrollment":80,"completionDate":"2026-12-14"},{"nctId":"NCT06009627","phase":"PHASE2,PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":["Breast Cancer"],"enrollment":119,"completionDate":"2025-09-11"},{"nctId":"NCT06084364","phase":"PHASE4","title":"Intraarticular Steroids, Saline and Occupational Therapy in People With CMC1 Osteoarthritis","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2023-11-03","conditions":["Osteoarthritis Thumb"],"enrollment":354,"completionDate":"2028-10"},{"nctId":"NCT07222462","phase":"NA","title":"A Superiority Trial of Radiofrequency Ablation for Low Back Pain","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-02-04","conditions":["Chronic Low Back Pain (CLBP)"],"enrollment":300,"completionDate":"2029-08"},{"nctId":"NCT02891603","phase":"PHASE1,PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":["Graft Vs Host Disease","GVHD"],"enrollment":40,"completionDate":"2022-04-18"},{"nctId":"NCT06790784","phase":"PHASE3","title":"Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR","status":"RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2025-08-04","conditions":["Proliferative Diabetic Retinopathy (PDR)"],"enrollment":426,"completionDate":"2031-08"},{"nctId":"NCT06832189","phase":"PHASE1","title":"EVR and EPO for Liver Transplant Tolerance","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-21","conditions":["Liver Transplant"],"enrollment":20,"completionDate":"2030-06-01"},{"nctId":"NCT07370233","phase":"PHASE2","title":"Triple Therapy Strategy for Managing Persistent Pain After Spinal Microdiscectomy","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-02-20","conditions":["Spinal Disk Injury"],"enrollment":63,"completionDate":"2025-09-23"},{"nctId":"NCT07369245","phase":"NA","title":"Techniques for Activating Consciousness (TAC) for Outpatients With Moderate to Severe Alcohol Addiction","status":"NOT_YET_RECRUITING","sponsor":"Versailles Hospital","startDate":"2026-01-15","conditions":["Alcohol Addiction"],"enrollment":98,"completionDate":"2028-01-15"},{"nctId":"NCT03467919","phase":"PHASE3","title":"The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-04-01","conditions":["Osteoarthritis, Knee","Knee Pain"],"enrollment":40,"completionDate":"2024-10-29"},{"nctId":"NCT06327581","phase":"NA","title":"Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata","status":"RECRUITING","sponsor":"Zagazig University","startDate":"2023-12-15","conditions":["Alopecia Areata"],"enrollment":88,"completionDate":"2026-12-30"},{"nctId":"NCT07363876","phase":"NA","title":"The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-12-29","conditions":["Arthritis","Ultrasonication","Intra-articular Injections","Rheumatology"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT06401317","phase":"PHASE2","title":"Corticosteroid Against Saline Injections for Thumb Osteoarthritis (CASITOA)","status":"RECRUITING","sponsor":"Université du Québec à Trois-Rivières","startDate":"2025-11-04","conditions":["Trapeziometacarpal Osteoarthritis"],"enrollment":40,"completionDate":"2028-12-31"},{"nctId":"NCT06079645","phase":"NA","title":"Lichen Sclerosus - Treatment With Triamcinolone Acetonide: Injections (Syringe and Needle) x Micro Injections (MMP Technique)","status":"COMPLETED","sponsor":"Clinica Dermatologica Arbache ltda","startDate":"2023-10-20","conditions":["Lichen Sclerosus of External Female Genital Organs"],"enrollment":20,"completionDate":"2025-06-14"},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":["Psoriasis","Atopic Dermatitis"],"enrollment":10,"completionDate":"2030-06-01"},{"nctId":"NCT07347041","phase":"NA","title":"Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-01","conditions":["Myofascial Trigger Points","Chronic Musculoskeletal Pain","Hip Osteoarthritis"],"enrollment":1036,"completionDate":"2027-06-01"},{"nctId":"NCT07347028","phase":"NA","title":"Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-01","conditions":["Myofascial Trigger Points","Migraine","Cervicogenic Headache","Chronic Musculoskeletal Pain"],"enrollment":1036,"completionDate":"2027-06-01"},{"nctId":"NCT06731504","phase":"EARLY_PHASE1","title":"HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-12","conditions":["Hematologic Malignancy"],"enrollment":10,"completionDate":"2028-07"},{"nctId":"NCT06362226","phase":"PHASE1","title":"Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-02-28","conditions":["Periorbital Burns"],"enrollment":10,"completionDate":"2027-01"},{"nctId":"NCT07347067","phase":"NA","title":"Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-01","conditions":["Myofascial Trigger Points","Chronic Migraine Headache","Greater Occipital Nerve Block"],"enrollment":1036,"completionDate":"2027-06-01"},{"nctId":"NCT07347054","phase":"NA","title":"Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Shoulder Osteoarthritis(OA)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-01","conditions":["Myofascial Trigger Points","Chronic Musculoskeletal Pain","Shoulder Osteoarthritis"],"enrollment":1036,"completionDate":"2027-06-01"},{"nctId":"NCT07347730","phase":"NA","title":"Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Cervicogenic Headache","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-01","conditions":["Myofascial Trigger Points","Cervicogenic Headache","Dorsal Root Ganglion"],"enrollment":1036,"completionDate":"2027-06-01"},{"nctId":"NCT03914092","phase":"PHASE4","title":"Intralesional Steroid Injection Versus Voice Therapy in Management of Vocal Nodules","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-29","conditions":["Vocal Nodules in Adults"],"enrollment":50,"completionDate":"2023-08-28"},{"nctId":"NCT06734975","phase":"PHASE2","title":"Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-07-11","conditions":["Vocal Cord Disease","Vocal Cord Polyp","Vocal Cord Cyst"],"enrollment":28,"completionDate":"2026-12"},{"nctId":"NCT05669001","phase":"PHASE2","title":"A Study of TCD601 in de Novo Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2023-12-28","conditions":["Renal Transplantation"],"enrollment":76,"completionDate":"2026-04"},{"nctId":"NCT07333287","phase":"PHASE2","title":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2026-02-01","conditions":["Pancreatic Cancer Liver Metastases","Immunotherapy-naive"],"enrollment":38,"completionDate":"2028-11-30"},{"nctId":"NCT06735027","phase":"NA","title":"Corticosteroid Injection Versus Nerve Block","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-01-02","conditions":["Glenohumeral Arthritis","Rotator Cuff Arthropathy"],"enrollment":40,"completionDate":"2027-01-02"},{"nctId":"NCT07326098","phase":"NA","title":"Efficacy of Ultrasound-Guided Genicular Nerve Block in Patients With Gonarthrosis: A Randomized, Placebo-Controlled, Double-Blind Study","status":"RECRUITING","sponsor":"Ege University","startDate":"2025-11-01","conditions":["Gonarthrosis; Primary"],"enrollment":30,"completionDate":"2026-12-01"},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":["Graft-versus-host-disease","GVHD","GVHD, Acute"],"enrollment":45,"completionDate":"2023-07-25"},{"nctId":"NCT03794635","phase":"NA","title":"An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-12-20","conditions":["Metastatic Cancer","Locally Advanced Cancer","Thoracic Cancer","Gynecologic Cancer","Genitourinary Cancer","Lymphoma"],"enrollment":45,"completionDate":"2026-12"},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":["Acute Myeloid Leukemia","Acute Lymphocytic Leukemia","Biphenotypic/Undifferentiated Leukemia","Chronic Myelogenous Leukemia","Myelodysplasia","Relapsed Large Cell Lymphoma","Mantle Cell Lymphoma","Hodgkin Lymphoma","Burkitt Lymphoma","Relapsed T-Cell Lymphoma","Lymphoplasmacytic Lymphoma"],"enrollment":22,"completionDate":"2026-12-01"},{"nctId":"NCT07307846","phase":"NA","title":"Investigation of the Effects of Interlaminar Epidural Steroid Injection on Upper Extremity Proprioception in Patients With Chronic Cervical Radiculopathy","status":"RECRUITING","sponsor":"Marmara University","startDate":"2026-01-05","conditions":["Cervical Radiculopathy","Cervical Radicular Pain","Proprioception"],"enrollment":46,"completionDate":"2026-05-01"},{"nctId":"NCT07311759","phase":"PHASE3","title":"Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-08-17","conditions":["Chronic Paronychia"],"enrollment":21,"completionDate":"2026-05"},{"nctId":"NCT06362005","phase":"PHASE4","title":"The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-05-01","conditions":["Lichen Planus, Oral"],"enrollment":50,"completionDate":"2025-10-01"},{"nctId":"NCT06491745","phase":"NA","title":"Is Adding Extracorporeal Shock Wave Therapy to Physiotherapy and Corticosteroid Injection Beneficial for Frozen Shoulder","status":"RECRUITING","sponsor":"Shin Kong Wu Ho-Su Memorial Hospital","startDate":"2024-08-01","conditions":["Frozen Shoulder","Corticosteroid Injection","Physical Therapy","Extracorporeal Shock Wave Therapy","Rehabilitation"],"enrollment":94,"completionDate":"2028-12-31"},{"nctId":"NCT07307326","phase":"NA","title":"Biomarker Feedback Intervention","status":"NOT_YET_RECRUITING","sponsor":"Penn State University","startDate":"2026-03-15","conditions":["High Risk Drinking","College Student Drinking"],"enrollment":150,"completionDate":"2027-05-15"},{"nctId":"NCT07305246","phase":"PHASE2","title":"Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2025-12","conditions":["Breast Cancer"],"enrollment":120,"completionDate":"2027-09"},{"nctId":"NCT03613532","phase":"PHASE1","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2018-10-24","conditions":["Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)","Chronic Myelomonocytic Leukemia (CMML)","MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)","Hematopoietic Stem Cell Transplant"],"enrollment":102,"completionDate":"2027-03-01"},{"nctId":"NCT06712290","phase":"NA","title":"Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy","status":"WITHDRAWN","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2024-11-25","conditions":["Rotator Cuff Tendinopathy"],"enrollment":0,"completionDate":"2025-12-17"},{"nctId":"NCT03568318","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-09","conditions":["Atopic Dermatitis"],"enrollment":1533,"completionDate":"2030-10-23"},{"nctId":"NCT06244212","phase":"NA","title":"Topical Treatment for Atopic Dermatitis","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-09-19","conditions":["Atopic Dermatitis"],"enrollment":30,"completionDate":"2027-07"},{"nctId":"NCT06977568","phase":"PHASE2","title":"A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip","status":"TERMINATED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2025-07-25","conditions":["Osteoarthritis of Hip"],"enrollment":1,"completionDate":"2025-10-16"},{"nctId":"NCT07294937","phase":"","title":"Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the \"All With Heart\" Association - Development of a Morocco-Specific Risk Score","status":"RECRUITING","sponsor":"Moroccan Society of Cardiology","startDate":"2025-10-01","conditions":["Cardiovascular Diseases (CVD)"],"enrollment":10000,"completionDate":"2026-10"},{"nctId":"NCT07290777","phase":"PHASE2","title":"VEL-101 to Prevent Rejection After Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Veloxis Pharmaceuticals","startDate":"2026-07","conditions":["Transplantation, Kidney"],"enrollment":120,"completionDate":"2028-10"},{"nctId":"NCT04126824","phase":"EARLY_PHASE1","title":"Effect of Addition of Steroids on Duration of Analgesia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2022-01-06","conditions":["Uterine Fibroids","Adenomyosis"],"enrollment":28,"completionDate":"2027-08-02"},{"nctId":"NCT07283874","phase":"PHASE4","title":"Does it Matter the Volume of Injectate on the Outcome of Ultrasound-guided Perineural Injection for Carpal Tunnel Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-12","conditions":["Carpal Tunnel Syndrome (CTS)"],"enrollment":35,"completionDate":"2027-12"},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":["Asses Immunosuppression Modulation on Renal Recovery Post LT"],"enrollment":71,"completionDate":"2024-09-30"},{"nctId":"NCT06615050","phase":"PHASE3","title":"A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-04-02","conditions":["Graft-versus-host Disease (GVHD)"],"enrollment":572,"completionDate":"2031-01-17"},{"nctId":"NCT07278323","phase":"PHASE4","title":"Frozen Shoulder and Hormone Replacement Therapy","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":["Adhesive Capsulitis of the Shoulder","Frozen Shoulder"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT07277998","phase":"NA","title":"Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Karachi Medical and Dental College","startDate":"2026-03","conditions":["Oral Submucous Fibrosis"],"enrollment":40,"completionDate":"2026-09"},{"nctId":"NCT07276802","phase":"PHASE4","title":"The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Research Insight LLC","startDate":"2025-12-05","conditions":["Post Cataract Surgery"],"enrollment":40,"completionDate":"2026-07-31"},{"nctId":"NCT07267039","phase":"","title":"Phenol Neurolysis Versus Local Anesthetic Plus Steroid Genicular Nerve Block in Knee Osteoarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Salim Sencar","startDate":"2025-05-01","conditions":["Knee Osteoarthritis","Genicular Nerve Block"],"enrollment":42,"completionDate":"2026-01-01"},{"nctId":"NCT07263100","phase":"NA","title":"Comparative Study Between Intralesional Corticosteroid Injection Alone and Combined Intralesional Corticosteroid Injection With Either Long-pluse Nd YAG or Erbium Yag for Treating Hypertrophic or Keloid Scars","status":"COMPLETED","sponsor":"Somdech Phra Nangchao Sirikit Hospital","startDate":"2023-05-01","conditions":["Hypertrophic Scar","Keloid","Laser"],"enrollment":20,"completionDate":"2024-01-31"},{"nctId":"NCT05190770","phase":"PHASE2","title":"A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-15","conditions":["Breast Cancer","Breast Cancer Stage","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","Breast Cancer Stage IV"],"enrollment":18,"completionDate":"2024-08-27"},{"nctId":"NCT07131813","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2025-10-10","conditions":["Oral Lichen Planus"],"enrollment":60,"completionDate":"2027-06-01"},{"nctId":"NCT07174167","phase":"NA","title":"Genicular Nerve Block in Chronic Knee Osteoarthritis","status":"COMPLETED","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2023-04-01","conditions":["Gonarthrosis; Primary","Genicular Nerve Block","Gonarthritis"],"enrollment":81,"completionDate":"2024-07-01"},{"nctId":"NCT07201766","phase":"NA","title":"The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.","status":"NOT_YET_RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-02","conditions":["Keloids Scars"],"enrollment":104,"completionDate":"2026-02-28"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous, Topical","formulation":"Cream, Implant","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"TRIAMCINOLONE ACETONIDE"},{"form":"IMPLANT","route":"SUBCUTANEOUS","productName":"Naltrexone"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000145980","MMSL":"4582","NDDF":"002188","UNII":"1ZK20VI6TY","VUID":"4017599","CHEBI":"CHEBI:9667","VANDF":"4017599","INN_ID":"755","RXNORM":"10759","UMLSCUI":"C0040864","chemblId":"CHEMBL1200449","ChEMBL_ID":"CHEMBL1451","KEGG_DRUG":"D00385","DRUGBANK_ID":"DB00620","PUBCHEM_CID":"31307","SNOMEDCT_US":"116594009","IUPHAR_LIGAND_ID":"2870","MESH_DESCRIPTOR_UI":"D014221"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"23%"},"publicationCount":10340,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"A01AC01","allCodes":["A01AC01","C05AA12","D07AB09","D07BB03","D07CB01","D07XB02","H02AB08","R01AD11","R03BA06","S01BA05","S02CA04"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":9,"_genericFilersChecked":true,"genericManufacturerList":["Barr","Impax Labs","Ivax Sub Teva Pharms","Mylan","Purepac Pharm","Roxane","Sandoz","Teva","Watson Labs"],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1957","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1957-12-03T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1978-03-09T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":"ANDA085692"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1983-05-04T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":"ANDA085691"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1984-03-19T00:00:00.000Z","mah":"CROWN LABS","brand_name_local":null,"application_number":"ANDA088042"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-10-05T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":"ANDA209852"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-08-18T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":null,"application_number":"ANDA216625"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":14,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:14:47.753413+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}